cyrilzakka/clinical-trials huggingface dataset:
Effects of Contrast Strength Training in Badminton Players

Badminton is one of the most popular sports worldwide. In general, badminton jumping actions have two goals: achieve maximum height and reach a precise location using certain body movements. Both objectives are important in badminton and must be considered when conducting practical training sessions and imparting techniques. The players should have agility to move on the court forward sideward and backward to do many actions with high speed. They require sports specific training to achieve power, stability and agility in the ground for a powerful performance. Contrast strength training is multi-intervention programs and it has a certain influence on agility, power and speed.A sample size of 48 badminton players from Pakistan Sports Board, university level and badminton club players will be taken through Non-Probability Convenience Sampling technique. Sample size of players with age group between 17-28 years will be taken. Players will be selected on the basis of inclusion and exclusion criteria and will be equally divided into two groups by random number generator table. Group A experimental group will perform contrast strength training. Group B participants of the control group will follow their standard badminton practice over the same duration with no strength training design. Before and after completion of the respective training agility and power will be assessed through t-test and vertical jump test. For explosive speed 40-yard dash will be performed. Data will be analyzed by using SPSS for Windows Version 25.

The aim of this study is to determine the effects of contrast strength training on agility, power and explosive speed in badminton players.

Eligibility Criteria:
Inclusion Criteria:

* • Both male and female athletes.

  * Participants between the age of 17-28.(10)
  * Have been playing on a regular basis three-four times a week(21)
  * Players must have been playing badminton for more than 2 years.(22)

Exclusion Criteria:

* Athletes with systemic and neuromuscular issue(1)
* Players have musculoskeletal problem which can hinder the trainings.(10)
* Received surgery in the three years prior to the study or had undergone rehabilitation within the past year.(1)
* Could not commit to full participation in the study's training regimes.
* Did not practice any training in the last six months(10)
* History of injury in past 6 months(10)
* Previous history of fracture, previous injury, open wounds.(10)
Perception of Facial Expression in Subjects With and Without Crow's Feet Lines

This study will examine the perception of facial expressions among individuals with and without crow's feet lines.


Eligibility Criteria:
Inclusion Criteria:

* English fluency

Exclusion Criteria:

* None
Efficacy of Limited Right Anterior Thoracotomy Versus Median Sternotomy for Mitral Valve Replacement

this study compare between two diffrent methods for approach mitral valve in mitral valve replacement throgh opening of the middle of the sternum by saw or through opening between 4th and 5th rib on the right side of the chest without saw

study the efficacy of mitral valve replacement by median sterntomy versus limited right thoractomy

Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with acquired isolated mitral valve disease requiring mitral valve replacement \> 18 years

Exclusion Criteria:

* patients with Previous cardiac surgery, • Patients less than 18 years, • Patients with other valvular heart lesions (aortic valve or tricuspid valve) , IHD Patients , Obese patients (BMI\>35), COPD patients
Safety Registry of a Fecal Microbiota Transplant Cohort

Clostridium difficile infection (CDI) is a major cause of infectious diarrhea and the most important cause of nosocomial diarrhea. Recurrent forms are a major problem with this infection. The use of fecal microbiota transplantation (FMT), FMT appears in the most recent European and North American recommendations.

There is no cohort or multicenter registry in France prospectively collecting FMTs, the methods used, their efficacy and side effects. Likewise, there is no prospective collection focused on the cohort of stool donors. A large national cohort of patients who have undergone FMT as part of routine care as well as donors, is essential for evaluating the safety of FMT.

Clostridium difficile infection (CDI) is a major cause of infectious diarrhea and the most important cause of nosocomial diarrhea. For 20 years, the incidence of CDI has continued to increase. In addition, the severity of infections is also increasing (mortality: 5% in 1990 against 13.8% in 2003; complications: 6% in 1990 against 18% in 2003).

Recurrent forms represent a major problem of this infection. Indeed, after a first episode, the risk of a first recurrence is around 15 to 25% and this risk then increases with each recurrence, reaching 45% then 65% after a first and second recurrence respectively. These Recurrent forms pose a real therapeutic problem, causing significant morbidity (repeated hospitalizations, time off work, etc.) and substantial mortality. Patients with CDI are 2.5 times more likely to die within 30 days of infection than uninfected patients, regardless of age or comorbidities. The mortality rate is also higher in patients with a recurrent form than in those with a single episode. Furthermore, the antibiotics usually used are only marginally effective in cases of recurrent CDI.

Numerous studies, including two randomized trials, have shown that fecal microbiota transplantation (FMT), is superior to antibiotic therapy in reducing subsequent recurrences, the use of FMT in this indication appears in the most recent European and North American recommendations.

Cosmic-FMT cohort aims to be as representative as possible of the population of patients having FMT for CDI in the context of care.

Eligibility Criteria:
Inclusion Criteria:

Patients :

* Adult patient with an indication for FMT for CDI (severe refractory CDI, recurrent CDI);
* Informed written consent

Donors:

* Adult (18 years or older)
* Informed Written consent

Exclusion Criteria:

* insufficient level of understanding of written and spoken French language
Study to Evaluate the Effects of XXS on Oxidative Stress in Patients With Mild or Moderate Hyperlipidemia

Given preliminary data in animal (proprietary data) have shown that XXS (a mixture of natural polyphenolic extracts of edible plants) has a significant and favourable effect on oxidative stress notably with a decrease in certain markers of oxidative stress and on plasma lipid parameters, the investigator proposes to study the effect of 6 months of treatment with XXS in a controlled study against placebo in a population of persons presenting a lipid profile at the upper limit of normal.


Eligibility Criteria:
Inclusion Criteria:

* Persons who have provided written consent
* Persons aged over 18 years
* Presenting LDL levels between 1.30 and 1.90 g/l and/or triglyceride levels between 1.5 and 3 g/l

Exclusion Criteria:

* Persons without national health insurance cover
* Pregnant or breastfeeding women
* Adults under guardianship
* Patients with diabetes (Insulin-Dependent Diabetes (IDD) or Non-Insulin-Dependent Diabetes NIDD)
* Patients with coronary artery disease
* Patients with atherosclerosis
* HDL\>0.80 g/l
* receiving treatment with lipid-lowering agents (statins, fibrates, ezetimibe or Ω3)
* Consuming vitamin supplements (A, C, E...)
* Consuming oligoelements or minerals (Se, Zn, Ca...)
* Renal insufficiency (creatinine clearance \< 30 ml/min calculated according to the Modification of the Diet in Renal Disease (MDRD))
BIBR 277 Capsules in Hypertensive Patients With Nephropathy

The antihypertensive effect, safety and usefulness of treatment with BIBR 277 capsules were evaluated in hypertensive patients with nephropathy


Eligibility Criteria:
Inclusion Criteria:

* Condition: Either of the following criteria is satisfied in laboratory tests:

  * Presence of a renal parenchymal disorder such as chronic glomerulonephritis is confirmed (serum creatinine \< 3.0 mg/dL)
  * Presence of a renal function disorder (serum creatinine ≥ 1.5 mg/dL to \< 3.0 mg/dL)
* Age: ≥ 20 years
* Sex: Either male or female
* Patient status: Either outpatients or inpatients. However, the patient status should remain unchanged throughout the study period
* Blood pressure (BP):

  * \[Outpatients\] The last 2 measurements of sitting BP out of at least 3 taken during the observation period (2 - 4 weeks) should be stable and a mean of the two measurements should be ≥160 mmHg for systolic BP (SBP) and ≥95 mmHg for diastolic BP (DBP)
  * \[Inpatients\] The last 2 measurements of supine BP taken during the observation period (1 week) should be stable and a mean of the 2 measurements should be ≥ 150 mmHg for SBP and ≥ 90 mmHg for DBP

Exclusion Criteria:

* Renovascular hypertension
* Undergoing haemodialysis
* Severe hypertension (Diastolic BP ≥ 120 mmHg)
* Severe heart failure, angina pectoris, or history of myocardial infarction
* Atrioventricular conduction disturbance (degree II to III), atrial fibrillation, or serious arrhythmia
* Symptoms of cerebrovascular disorder
* Serious hepatic dysfunction
* Uncontrolled diabetes
* Peptic ulcer
* History of hypersensitivity to drugs
* Hyperkalaemia
* Undergoing treatment with a digitalis preparation
* Pregnant, breast feeding, possibly pregnant or planning to become pregnant during this study
* Otherwise judged ineligible by the investigator
Application of the Propofol Precise Infusion Model

Propofol is one of the most commonly used anesthetics in the world. However, the dose-response of propofol was remarkable variety. Herein, this study aims to investigate the possible association of gene polymorphism and propofol susceptibility, and to research more precise infusion model of this drug.

Patients undergoing gastrointestinal endoscopy will be recruited. Anesthesia is induced with propofol via TCI at 1.5µg/ml, and increases 0.5µg/ml for every 3min until OAA/S score 0. During this period, OAA/S score will be evaluated every 1min until OAA/S score 0. At this moment, the blood concentration of propofol, the doses of propofol, the onset time and BIS are recorded, and blood sample for gene polymorphism detection were required.

Eligibility Criteria:
Inclusion Criteria:

1. patients who undergoing gastrointestinal endoscopy with anesthesia
2. age ≥18 years

Exclusion Criteria:

1. hepatic or kidney function injured;
2. received hypnotic sedative drug regularly;
3. Pregnancy, excessive drinking, or current smoker;
4. be allergic to propofol
5. patients who with difficulty communication
Comparative Evaluation of Osteopathy Treatment Efficacy in Pain Support After Breast Surgery in Oncology

This is an open, prospective, controlled, randomized, comparative study with 2 arms.

The purpose of the study is to assess the efficacy of osteopathy after breast surgery.

80 patients will be enrolled, 40 per arm. Patients will be randomized at inclusion and will be followed during one year.


Eligibility Criteria:
Inclusion Criteria:

* woman \>= 18 years
* pain (median VAS \>=3 on the week prior to inclusion)
* mastectomy or tumorectomy with axillary dissection \<= 12 months
* PS \<=2
* able to write, understand and read French
* signed informed consent

Exclusion Criteria:

* no pain
* immediate breast reconstruction
* history of cognitive or psychiatric troubles
A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)

The primary objective of the 1701-202 STRONG SCD study is to evaluate the safety and tolerability of different dose levels of IW-1701 compared with placebo when administered daily for approximately 12 weeks to patients with stable SCD. Exploratory objectives include evaluation of pharmacokinetic (PK) as well as evaluation of the effect of IW-1701 on symptoms of SCD, health-related quality of life, and biomarkers of pharmacodynamic (PD) activity.


Eligibility Criteria:
INCLUSION CRITERIA

1. Patient is ambulatory male or female 16 to 70 years of age at the Screening Visit.
2. Patient has SCD, including homozygous hemoglobin S (HbSS), hemoglobin SC disease (HbSC), heterozygous hemoglobin S-beta zero (HbSβ0)-thalassemia, or heterozygous hemoglobin S-beta plus (HbSβ+)-thalassemia, documented in their medical history.
3. If patient is on medication(s) for SCD, such as hydroxyurea (HU), are on a stable regimen.
4. Per medical history and/or patient recall, patient has had at least 1 and no more than 10 sickle cell-related pain crises in the 12 months before the Screening Visit and none occurring in the 4 weeks before the Randomization Visit.
5. Patient completes daily eDiary entries for at least 10 days during the last 14 days of the Run in Period as assessed at the Randomization Visit.
6. Women of childbearing potential must have a negative pregnancy test prior to randomization and must agree to use protocol-specified contraception from the Screening Visit through 90 days after the final dose of study drug.
7. Male patients must be surgically sterile by vasectomy (conducted ≥60 days before the Screening Visit or confirmed via sperm analysis) or must agree to use protocol-specified contraception and agree to refrain from sperm donation from the Screening Visit through 90 days after the final dose of study drug.

EXCLUSION CRITERIA

1. Patient requires a program of prescheduled, regularly administered chronic blood transfusion therapy.
2. Patient has been hospitalized for an SCD-related complication in the 4 weeks before the Randomization Visit.
3. Patient has taken opioid(s) \>200 morphine mg equivalent/day within the 4 weeks before the Randomization Visit.
4. Patient is taking aspirin ≥325 mg daily, P2Y12 inhibitors, any anticoagulant medication, specific inhibitors of phosphodiesterase 5 (PDE5), nonspecific inhibitors of phosphodiesterase 5 (PDE5), moderate or strong cytochrome P450 3A (CYP3A) inhibitors, any supplements for the treatment of erectile dysfunction, riociguat, or nitrates or nitric oxide donors in any form.
5. Patient has major concurrent illness or medical condition that in the opinion of the Investigator would preclude participation in a clinical study.

NOTE: Other inclusion and exclusion criteria apply, per protocol
A Study to Evaluate the Efficacy and Safety of KH001 in Patients with Dentin Hypersensitivity

The purpose of this study is to evaluate the efficacy and safety of KH001 in patients with dentin hypersensitivity.

This study is multicenter, double-blind, placebo-controlled, randomized, parallel-designed, phase 2 study to evaluate the efficacy and safety of KH001. The total duration of the study will be approximately 7 to 11 weeks. Clinical safety evaluations will include physical examinations, vital signs, clinical laboratory results, and Adverse Event monitoring.

Eligibility Criteria:
Inclusion Criteria:

* Is at least 19 years old by the time of the screening visit
* Be in good general health as determined by the investigator
* Have at least 2 non-adjacent teeth and is diagnosed with hypersensitive

Exclusion Criteria:

* Is allergic to the active drug substance or other excipients used in the investigational product
* Has any history of alcohol or drug abuse
* Has received any treatment related to dentin hypersensitivity within 8 weeks prior to the screening visit
* Has active dental caries or history of dental caries
Characterizing the Microbiome in Postmenopausal Women With Vulvar Lichen Sclerosus

Vulvar lichen sclerosus (LS) is a chronic inflammatory disease, often diagnosed at late stages after scarring has obliterated normal vulvar architecture and severely affected a woman's quality of life. First line therapy for vulvar LS is ultrapotent topical steroids. If left untreated, this condition can cause complete stenosis of the vaginal introitus and 5% of patients may develop squamous cell carcinoma (SCC).

Lichen sclerosus is more common in pre-pubertal children and in post-menopausal women suggesting that hormonal shifts may contribute to disease pathogenesis. Small studies in children with LS have also shown that the microbiome is altered in LS. Little is known about the skin microbiota in postmenopausal patients with vulvar LS.

To determine if the microbiome is altered in vulvar skin of postmenopausal patients with LS, this study will use 16s sequencing to broadly characterize the microbiota of vulvar skin with LS compared to control vulvar skin. The study team hypothesizes that patients with vulvar LS will have a unique vulvar microbial signature compared to age-matched controls. This study also seeks to elucidate differences in the vulvar microbiome of patients with LS after treatment of their underlying condition. The study team hypothesizes that the vulvar microbiome will change after treatment for vulvar LS.

Vulvar dermatoses are an understudied area in dermatology with limited therapeutic options. Innumerable women often suffer in silence with vulvar LS. The long-term goal of this work is to understand factors that contribute to vulvar LS so that intervention may be undertaken before irreversible scarring and SCC develop.


Eligibility Criteria:
Inclusion Criteria:

* Postmenopausal

Exclusion Criteria:

* Use of systemic hormone replacement
* Use of antibiotics in prior three months
* Urinary incontinence, which is defined by: 1) two incontinence episodes in the past three days and also 2) regular incontinence over the past three months that has necessitated use of incontinence protection garments
A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema

This is a multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, three parallel group, 36-week study in participants with center-involving diabetic macular edema (DME). Only one eye will be selected as the study eye. Where both eyes meet all eligibility criteria, the eye with the worse best corrected visual acuity (BCVA) will be defined as the study eye. The study will consist of a treatment period (20 weeks) and an observational period (up to 16 weeks). Treatment naive participants will be randomized in a 1:1:1 ratio to one of the Arms A, B and C, respectively. Participants previously treated with intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) will be randomized in a 1:1 ratio to Arms A and C.


Eligibility Criteria:
Inclusion Criteria:

* Macular edema associated with diabetic retinopathy
* Decreased visual acuity attributable primarily to DME
* Diagnosis of diabetes mellitus

Exclusion Criteria:

* High risk proliferative diabetic retinopathy
* Cataract surgery within 3 months of Baseline, or any other previous intraocular surgery
* Uncontrolled glaucoma
* Current or history of ocular disease in the study eye other than DME
* Major illness or major surgical procedure within 1 month prior to Day 1
* Uncontrolled blood pressure
* Glycosylated hemoglobin (HbA1c) greater than (\>) 12 percent (%) at screening
* Untreated diabetes mellitus or initiation of oral anti-diabetic medication or insulin within 4 months prior to Day 1
Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

The purpose of this study is to evaluate the effects of Delafloxacin versus Vancomycin plus Aztreonam in the treatment of patients with acute bacterial skin and soft tissue infections.

The purpose of this study is to determine if delafloxacin, an investigational drug, is safe and effective in the treatment of skin and nearby tissue infections compared with a combination of other antibiotics, vancomycin and aztreonam.

Eligibility Criteria:
Inclusion Criteria:

* Adult (≥ 18 years of age) men or women with a diagnosis of ABSSSI (cellulitis/erysipelas, wound infection, major cutaneous abscess, or burn infection) with surrounding redness of a minimum surface area of 75 cm\^2 and at least two signs of systemic infection
* In the opinion of the investigator, the subject must require and be a suitable candidate for IV antibiotic therapy, and the subject must be able and willing to comply with protocol requirements

Exclusion Criteria:

* A medical history of significant hypersensitivity or allergic reaction to quinolones, beta-lactams, vancomycin, or vancomycin derivatives according to the judgment of the investigator.
* Women who are pregnant or lactating.
* Any chronic or underlying skin condition at the site of infection that may complicate the assessment of response, including infection involving a prosthetic joint, human or animal bite, osteomyelitis, decubitus ulcer, diabetic foot ulcer, septic arthritis, mediastinitis, necrotizing fasciitis, anaerobic cellulitis, or synergistic necrotizing cellulitis, myositis, tendinitis, endocarditis, sustained shock, gangrene or gas gangrene; burns covering ≥10% of body surface area; severely compromised immune system, severely impaired arterial blood supply to an extremity with an ABSSSI, deep vein thrombosis or superficial thrombophlebitis, and requiring either an amputation or multiple debridement procedures.
* Receipt of systemic antibiotic therapy in the 14 days before enrollment unless 1 of the following was documented:

  * Received ≥ 48 hours of antibiotic therapy for ABSSSI AND clinical progression is documented (i.e., not by patient history alone).
  * Recently (within 14 days) completed a treatment course with an antibacterial drug for an infection other than ABSSSI and the drug does not have activity against bacterial pathogens that cause ABSSSI.
  * Received only 1 dose of either a single, potentially effective, short-acting antimicrobial drug or drug regimen for ABSSSI.
* Any underlying disease that, in the opinion of the investigator, could interfere with the subject's ability to participate in the study including severe cardiac disease, known history of liver disease, end-stage renal disease, malignancy, psychiatric disorder, ongoing treatment for seizures or untreated history of seizures, or life expectancy of \< 3 months.
Genetic Modifiers for 22q11.2 Syndrome

The purpose of the project is the determination of how the deletion of DNA from chromosome 22 at the q11.2 band causes the phenotypes observed in velo-cardio-facial syndrome (VCFS). In other words, the purpose remains genotype-to-phenotype matching. Current methods includes the use of whole genome chips and microarray analysis. Blood samples are collected for DNA from every patient who consents from the VCFS Center at Upstate Medical University. They are examined for phenotypic features consistent with our typical clinical evaluation. The information from these examinations will be entered anonymously into a database. Genomic information is then matched to clinical phenotype with appropriate statistical method applied.


Eligibility Criteria:
Inclusion Criteria:

* FISH confirmed diagnosis of 22q11.2 deletion syndrome

Exclusion Criteria:

* none